CHF P3 Trial Accrues Sufficient Primary Endpoint Events
Filed with ASX · · 2 pages · English
Earlier from Mesoblast
- MSB Provides Q1 Financial Results and Operational Highlights
- MSB and Lonza Enter GVHD Commercial Manufacturing Agreement
- Mesoblast Raises A$75 Million
- Grunenthal and MSB Enter Strategic Partnership for Back Pain
- Mesoblast Reports on Annual Results
Later from Mesoblast
- CHF P3Trial Accrues Sufficient Primary EndPt Events(Correct)
- DMC Completes Final Review of Phase 3 Heart Failure Trial
- MSB Files GvHD Clinical Efficacy and Safety Data with US FDA
- Appendix 4C - quarterly
- Mesoblast Submits Completed BLA for Ryoncil to US FDA
Follow Mesoblast into a list and get an email when it puts out news.
Follow Mesoblast